Mersana Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10 2022 - 8:00AM
Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that the
Company’s management team will participate in a fireside chat at
the 11th Annual SVB Leerink Global Healthcare Conference on
Thursday, February 17, 2022 at 10:40 a.m. ET.
A live webcast of the presentation will be available on the
Investors & Media section of Mersana’s website at
www.mersana.com. An archived replay will be available for
approximately 30 days following the presentation.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to rapidly develop
novel ADCs with optimal efficacy, safety and tolerability to
meaningfully improve the lives of people fighting cancer. Mersana’s
lead product candidate, upifitamab rilsodotin (UpRi), is a
Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a
single-arm registration strategy in patients with
platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1
umbrella study in combination with other ovarian cancer therapies.
XMT-1592, Mersana’s second ADC product candidate targeting
NaPi2b-expressing tumors, was created using Mersana’s customizable
and homogeneous Dolasynthen platform and is in the dose escalation
portion of a Phase 1 proof-of-concept clinical study. The Company’s
early-stage programs include XMT-1660, a Dolasynthen ADC targeting
B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the
Company’s Immunosynthen platform and targeting a novel epitope of
human epidermal growth factor receptor 2 (HER2). In addition,
multiple partners are using Mersana’s platforms to advance their
ADC pipelines. Mersana Therapeutics was recently named among the
2021 Top Places to Work in Massachusetts by the Boston Globe. The
Company routinely posts information that may be useful to investors
on the “Investors and Media” section of our website at
www.mersana.com.
Contact:
Investor & Media ContactJames Salierno,
617-498-0020jsalierno@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024